The University of Texas Health Science Center at Houston (UTHealth) has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child’s own umbilical cord blood stem cells for traumatic brain injury in children. The study is being performed in conjunction with Children’s Memorial Hermann Hospital, UTHealth’s primary children’s teaching hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cordblood/48021/
The Ad Council is joining the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), to debut their first joint national multimedia public service campaign to help families prevent food poisoning in the home.
The Food Safe Families campaign was announced this morning by USDA Secretary Tom Vilsack and HHS Secretary Kathleen Sebelius in time for the July 4th holiday and the start of summer when foodborne illnesses tend to increase—a time when many families celebrate with food. It’s also a time when foodborne illnesses tend to increase with more outdoor meals, and other factors that increase the risk for disease-causing bacteria in food.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50582/
A page turning, timely novel that perfectly captures the anxieties of plunging into the criminal underworld and the zeitgeist of the recession generation, Mule is about young people trying to make do in a moment when the American Dream they never had to believe in, because it was handed to them, fully wrapped and ready to go at the take out window, suddenly vanished from the menu. Learn more about this book here, http://bit.ly/o7MZ3v and its author here, http://www.tonydsouza.com/ fiction
According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
http://www.miraclemulti.com MiracleMulti™ The Best Multivitamins on the market for Men, Women, Vegetarians, and Bodybuilding. Once a day Multivitamin for Health, Energy, Focus, Well Being and Anti-aging.***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
http://youtu.be/tHPU2gR_RiI blu cigs National TV ad - I like to smoke but my old cigarettes kept me from smoking where I wanted to. blu electronic cigarettes are different. They have no ash and no offensive odor, so I can enjoy them anywhere. In my car, at work, at my favorite restaurant or even at my friends house. blu has lot's of great USA made flavors and come in four different strengths so I can control my nicotine intake and it cost less than regular cigarettes. blu is the smarter alternative to cigarettes and the best way to take back you're freedom. blu Cigs are available at many fine retailers including, Sheetz, Ingles, Kerr Drug, Harps, Cumberland Farms, H-E-B, Scolari's and Couche-Tard.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Undercover police officers: Magic Simpson and Chad Holland respond to a drug deal behind a building of a Kroger grocery store. The suspects are armed and dangerous. The officers must be aware before they attempt to arrest the dealers for selling dope.
Magicsimpson1 Productions 2012
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
